Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin 10% - Grifols

Drug Profile

Immune globulin 10% - Grifols

Alternative Names: Gammaked; Gamunex; Gamunex-C; Gamunex-IGIV; IGIV; Intravenous gammaglobulin; IVIG; IVIG 10% - Kedrion; Kedrion Immunoglobulin 10%; Kedrion IVIG 10%; KIg10; TAL-05-0002

Latest Information Update: 06 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; Beth Israel Deaconess Medical Center; Grifols; Kedrion; University of Texas Southwestern Medical Center
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Myasthenia gravis
  • Phase II COVID 2019 infections; Diabetic neuropathies
  • Phase I/II Tachycardia
  • Discontinued Multiple sclerosis

Most Recent Events

  • 17 Sep 2020 Phase-II clinical trials in COVID-2019 infections (Adjunctive treatment) in USA (IV) (NCT04480424)
  • 09 Sep 2020 Phase-III clinical trials in Immunodeficiency disorders (In adolescents, In children) in Hungary (IV) (EudraCT2020-001496-32)
  • 25 Mar 2020 Grifols plans a clinical study for COVID-2019 infections in Spain (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top